|
FDA Gives Complete Response to J&J’s Simponi sBLA
Johnson and Johnson (J&J) subsidiary Janssen Biotech has received a complete response letter for its Simponi sBLA, intended to expand the inflammatory disease drug’s label to include inhibiting the progression and maintenance of reduction of signs and symptoms of rheumatoid arthritis (RA).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives